Similar results were found in a clinical study in patients with T2DM, where administration of liraglutide, but not metformin, increased the relative abundance of Akkermansia , which is often associated with the improvement of gastric mucosa and also becomes severely depleted in diabetic patients [115]
Although this medication is not yet FDA-approved for the treatment of obesity, it was granted fast track designation for this indication in October 2022 and current results look promising
A broader review of real-world evidence puts first-year discontinuation across studies in the range of 20% to 50%, with real-world weight outcomes generally falling below trial results, except among the most adherent patients, whose outcomes approach what trials reported
Here are things to do to support GLP-1: Exercise GLP-1 levels have been shown to increase after moderate exercise, helping with appetite control and post-meal satiety
Since 2014, Semaglutide GLP-1 injections have been FDA-approved for use as a means to supplement weight loss for those who are obese or who suffer from weight-related medical problems